| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0168-8278(99)80398-5 |
| P8608 | Fatcat ID | release_3kvds6vgl5cm5jgfuz6s34d7yu |
| P698 | PubMed publication ID | 10622584 |
| P2093 | author name string | Brouwer JT | |
| Schalm SW | |||
| Bekkering FC | |||
| van Rossum TG | |||
| P2860 | cites work | Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 |
| Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients | Q34415766 | ||
| Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. | Q36865888 | ||
| Therapy of hepatitis C: re-treatment with alpha interferon | Q40882243 | ||
| Evaluation of efficacy of antiviral therapy for chronic hepatitis C: a EUROHEP Consensus Report on response criteria | Q41207110 | ||
| Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial | Q41839327 | ||
| A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 | ||
| Prolonged therapy of chronic hepatitis C with ribavirin | Q42552575 | ||
| Re-treatment of chronic hepatitis C with consensus interferon . | Q42675525 | ||
| Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy | Q42985646 | ||
| Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison | Q42985824 | ||
| Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group | Q42987938 | ||
| Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients | Q42989126 | ||
| Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy | Q42989131 | ||
| A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. | Q43036080 | ||
| A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group | Q43039883 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity | Q45757472 | ||
| Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa | Q45761962 | ||
| Hepatitis C: viral kinetics. | Q52252598 | ||
| The long term efficacy of glycyrrhizin in chronic hepatitis C patients. | Q53444006 | ||
| Treatment of chronic hepatitis C with amantadine | Q73671703 | ||
| P921 | main subject | chronic hepatitis | Q62019625 |
| P304 | page(s) | 184-188 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | New treatment strategies in non-responder patients with chronic hepatitis C. | |
| P478 | volume | 31 Suppl 1 |
| Q50571707 | A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. |
| Q43032141 | Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate |
| Q40150894 | Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model. |
| Q43712734 | Licorice for hepatitis C: yum-yum or just ho-hum? |
| Q33870245 | Pathogenesis, diagnosis and management of hepatitis C. |
| Q94329071 | Treatment Options in Patients with Chronic Hepatitis C |
Search more.